Medical Research Council

Funders and NGOs find new reporting standards favorable

Tuesday, May 30, 2017

According to the World Health Organization (WHO), some of the world’s largest funders of medical research and international non-governmental organizations (NGOs) recently agreed on new standards for clinical trials outcomes. Funded all clinical trials, per these new standards, are required to be registered with all results publicly disclosed. By all indications, funders and NGOs who agreed to the new standards find the new requirements favorable.

[Read More]

FEI partners to form Cryo-EM research consortium

Tuesday, April 5, 2016

FEI has partnered to form the “Cambridge Pharmaceutical Cryo-EM Consortium.” Partners include five pharmaceutical companies—Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Center. As part of the three-year agreement, FEI will provide sample preparation and data collection services on a Titan Krios cryo-transmission electron microscope (cryo-EM) to the consortium companies for early-stage drug discovery research.

[Read More]

MRC, GSK, five U.K. universities collaborate on difficult disease areas

Wednesday, July 15, 2015

Medical Research Council (MRC), GlaxoSmithKline and five U.K. universities are collaborating on difficult disease areas. The Experimental Medicine Initiative to Explore New Therapies (EMINENT) network will be coordinated by University College London (UCL) and will bring together teams of researchers from the Universities of Cambridge, Glasgow, Newcastle, Imperial College London and UCL with GSK researchers to study the fundamental biological mechanisms responsible for a range of inflammatory diseases.

[Read More]

Forma Therapeutics, Cancer Research Technology form two virtual companies

Wednesday, March 25, 2015

Forma Therapeutics, headquartered in Watertown, Mass., and Cancer Research Technology (CRT) have formed two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, drug discovery scientists and a development network.

[Read More]

U.K. announces $21M investment in stratified medicine

Friday, January 30, 2015

Minister for Life Sciences George Freeman has announced a further $20.6 million investment in stratified medicine collaborations funded by the Medical Research Council (MRC). Four new awards bring the total of stratified medicine consortia funded by the MRC to 13, with investments totaling over $21 million—part of the government’s $195.4 million commitment to stratified medicine set out in the U.K. life sciences strategy.

[Read More]